Molecular Devices Releases Breakthrough TUNE Technology, Now Part of the SpectraMax Paradigm Multi-Mode Microplate Detection Platform
Sunnyvale, CA - September 1, 2011 - Today, Molecular Devices, a leading provider of instruments, software, and consumables for drug discovery and life sciences research, announced the addition of the TUNE detection cartridge to the SpectraMax Paradigm Multi-Mode Microplate Detection Platform. The breakthrough technology of TUNE with wavelength flexibility in a monochromator device and up to 10x the sensitivity will benefit both the research and screening markets.
The SpectraMax Paradigm Detection Platform is the only user upgradeable microplate reader on the market today. It allows the user to read what they want, when they want. Now, with the TUNE detection cartridge, the Paradigm system is the most flexible instrument available. The patent pending Spectral Optimization Wizard in SoftMax® Pro software reduces the assay set up time by more than 50% with simultaneous scanning of excitation and emission spectrums.
Flexibility for Research
For the researchers who need the wavelength flexibility of a monochromator in fluorescent applications, TUNE will offer unmatched sensitivity allowing them to test new assays and further advance their research. The flexibility of the Paradigm platform and ability to easily add future options, makes it a great investment for their labs.
Speed of Paradigm with Sensitivity of TUNE, Ideal for Screening
The TUNE cartridge enables monochromator-like wavelength flexibility without compromising on sensitivity. The Paradigm platform is built with on-the-fly detection for reduced read times, plate format of up to 1536-wells, dual PMTs, and was designed with automation in mind, all important features for high throughput. Use of the TUNE cartridge with the Paradigm instrument will meet the needs of screeners with high sensitivity and throughput demands.
"We are extremely excited about our TUNE technology, which provides unmatched fluorescence sensitivity with wavelength flexibility. It will open new possibilities to our customers and is a great addition to the SpectraMax Paradigm platform," said Mikey Kindler, Senior Director of BioResearch Marketing.
###